Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer
- PMID: 30080934
- DOI: 10.1002/phar.2168
Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer
Abstract
Study objective: To examine the risks and compare the occurrences of major long-term side effects (sexual dysfunction, bone fractures, diabetes, cardiovascular morbidity, acute myocardial infarction [MI], and dementia) in patients with prostate cancer who received androgen-deprivation therapy (ADT) with those who did not.
Design: Propensity score-matched retrospective cohort study using Medicare claims data.
Data source: National Cancer Institute's Surveillance, Epidemiology, and End Results Program-Medicare linked database.
Patients: A total of 201,797 patients 66 years or older who were diagnosed with any stage of prostate cancer between 1992 and 2009; of these, 94,528 patients received ADT; 107,269 patients did not.
Measurements and main results: We identified receipt of ADT and number of claims for ADT, and ascertained the long-term treatment-related side effects that occurred during 19 years of follow-up, from 1992-2010, from Medicare claims data. Cox proportional hazards models were used to estimate the incidences and hazard ratios (HRs) of newly developed side effects. Among all potential long-term side effects, the risk of bone fractures was highest (HR 1.39, 95% confidence interval [CI] 1.35-1.43), followed by diabetes (HR 1.21, 95% CI 1.18-1.24), dementia (HR 1.16, 95% CI 1.13-1.20), coronary heart disease (HR 1.12, 95% CI 1.09-1.14), and acute MI (HR 1.11, 95% CI 1.08-1.15) in those who received ADT compared with those who did not. The HRs for bone fractures and diabetes increased steadily as the number of ADT doses increased, indicating a linear trend in the dose-response relationship. Compared with patients who received active surveillance, ADT was associated with a 12% increased risk of sexual dysfunction (HR 1.12, 95% CI 1.05-1.20). The HR for sexual dysfunction increased to 1.68 (95% CI 1.59-1.77) when ADT was combined with radiation therapy and to 3.54 (95% CI 3.26-3.85) when ADT was combined with radiation and surgery.
Conclusion: The results of this study demonstrated that in men with prostate cancer, receipt of ADT was associated with higher risks of bone fractures, diabetes, dementia, coronary heart disease, acute MI, and sexual dysfunction than in those who did not receive ADT.
Keywords: androgen-deprivation therapy; bone fractures; prostate cancer; side effects.
© 2018 Pharmacotherapy Publications, Inc.
Similar articles
-
Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.JAMA Netw Open. 2019 Jul 3;2(7):e196562. doi: 10.1001/jamanetworkopen.2019.6562. JAMA Netw Open. 2019. PMID: 31268539 Free PMC article.
-
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.Cancer. 2007 Oct 1;110(7):1493-500. doi: 10.1002/cncr.22933. Cancer. 2007. PMID: 17657815
-
Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.Prostate Cancer Prostatic Dis. 2020 Sep;23(3):410-418. doi: 10.1038/s41391-019-0189-3. Epub 2019 Nov 29. Prostate Cancer Prostatic Dis. 2020. PMID: 31784699
-
Androgen deprivation therapy: evidence-based management of side effects.BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23351025 Review.
-
Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Cancer. 2009. PMID: 19399748 Review.
Cited by
-
Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study).BMJ Open. 2024 Mar 23;14(3):e084412. doi: 10.1136/bmjopen-2024-084412. BMJ Open. 2024. PMID: 38521521 Free PMC article.
-
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2024 Jan 2. doi: 10.1038/s41391-023-00785-w. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38167924
-
Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice.Chin Herb Med. 2023 Sep 4;15(4):485-495. doi: 10.1016/j.chmed.2023.05.003. eCollection 2023 Oct. Chin Herb Med. 2023. PMID: 38094009 Free PMC article. Review.
-
Determining the association of rurality and cardiovascular disease among prostate cancer survivors.Urol Oncol. 2023 Oct;41(10):429.e15-429.e23. doi: 10.1016/j.urolonc.2023.06.008. Epub 2023 Jul 16. Urol Oncol. 2023. PMID: 37455231
-
Barriers and applied activity, quality of life and self-efficacy in prostate cancer survivors 1 year after completing radiotherapy.Support Care Cancer. 2023 Apr 20;31(5):284. doi: 10.1007/s00520-023-07729-z. Support Care Cancer. 2023. PMID: 37079161 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical